Bayer Aktiengesellschaft (BAYZF)
OTCMKTS · Delayed Price · Currency is USD
35.05
+3.13 (9.81%)
Nov 24, 2025, 4:00 PM EST
Bayer Aktiengesellschaft Revenue
Bayer Aktiengesellschaft had revenue of 9.66B EUR in the quarter ending September 30, 2025, a decrease of -3.09%. This brings the company's revenue in the last twelve months to 45.87B, down -1.87% year-over-year. In the year 2024, Bayer Aktiengesellschaft had annual revenue of 46.61B, down -2.16%.
Revenue (ttm)
45.87B EUR
Revenue Growth
-1.87%
P/S Ratio
0.64
Revenue / Employee
499.28K EUR
Employees
91,864
Market Cap
34.64B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 46.61B | -1.03B | -2.16% |
| Dec 31, 2023 | 47.64B | -3.10B | -6.11% |
| Dec 31, 2022 | 50.74B | 6.66B | 15.10% |
| Dec 31, 2021 | 44.08B | 2.68B | 6.48% |
| Dec 31, 2020 | 41.40B | -2.15B | -4.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Mid-Atlantic Home Health Network | 27.00M |
| Silence Therapeutics | 25.83M |
| Tian'an Technology Group | 2.12M |
Bayer Aktiengesellschaft News
- 22 hours ago - DAX Remains Positive Despite Coming Off Early Highs; Bayer Soars Nearly 10% - Nasdaq
- 22 hours ago - European Stocks Gain With Boost From Dovish Fed Comments, Bayer - Financial Post
- 22 hours ago - Bayer stock jump 9% as stroke drug trial revives confidence in pipeline - Invezz
- 23 hours ago - Stocks to Watch Monday: Alibaba, Tesla, Alphabet, Bayer - The Wall Street Journal
- 23 hours ago - Bayer’s stock is jumping on secondary stroke drug’s trial success - MarketWatch
- 1 day ago - Bayer shares up more than 8% on revived fortunes for blood thinner - Reuters
- 1 day ago - Bayer Sees Positive Results in Study for Asundexian as Stroke Treatment - WSJ
- 1 day ago - Bayer's Asundexian Meets Primary Goals In Phase III Study In Secondary Stroke Prevention - Nasdaq